Table G-14Characteristics of one head-to-head pharmacotherapy trial omitted from main analyses because of high risk of bias

StudyArm Dose mg/Day (N)Duration (Weeks)Population
Trauma Type		Baseline PTSD SeverityaMean
Age (Y)		% Female
% Nonwhite
McRae et al., 2004233Nefazodone (100 mg to 600 mg) (18)
Sertraline (50 mg to 200 mg) (19)		12Male and female
Outpatient special mental health		68.9 to 73.84077

NR
a

When mean data for baseline PTSD severity were not reported for the total sample but were presented for each study arm, we provide the range across arms.

mg = milligram; N = number; NR = not reported; PTSD = posttraumatic stress disorder; Y= year.

From: Appendix G, Documentation of Trials Rated High Risk of Bias

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 207.
Forman-Hoffman V, Middleton JC, Feltner C, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.